Form 4: Amgen CEO Robert Bradway Transfers Shares Through Trusts and Gifts

Amgen's CEO, Robert Bradway, engaged in transactions involving the transfer of 276,000 common stock shares through gifts and grantor retained annuity trusts.

Summary

• Amgen CEO Robert Bradway reported several transactions involving the company's common stock on December 2, 2024.
• Bradway gifted 96,000 shares to irrevocable trusts for his children.
• He also transferred 90,000 shares to his own grantor retained annuity trust (GRAT) and another 90,000 shares to a spousal GRAT.
• These transactions resulted in changes in both direct and indirect ownership of Amgen stock for Bradway.
• The transactions did not involve any monetary exchange, with the price per share listed as $0 for the transfers.

Sentiment

Score: 7

Explanation: The document reflects standard executive financial planning and does not indicate any positive or negative sentiment towards the company. The transactions are routine and expected.

Positives

• The transactions are part of standard estate and financial planning practices for high-net-worth individuals.
• The use of trusts can provide tax benefits and long-term financial security for family members.
• The reporting of these transactions demonstrates transparency and compliance with SEC regulations.

Negatives

• The transactions do not indicate any negative sentiment towards the company's future prospects.
• The transfers do not represent a sale of shares, so there is no negative impact on the market.

Risks

• There are no immediate risks associated with these transactions.
• The use of trusts and GRATs can be complex and may have future tax implications that are not detailed in this document.

Industry Context

These types of transactions are common for executives of publicly traded companies as part of their personal financial planning and estate management. They do not reflect any change in the company's performance or outlook.

Comparison to Industry Standards

• Executives at comparable companies such as Gilead Sciences, AbbVie, and Regeneron often use similar strategies for managing their stock holdings.
• The use of GRATs and trusts is a standard practice for high-net-worth individuals to manage their assets and minimize tax liabilities.
• These transactions are consistent with typical executive compensation and financial planning practices in the biotechnology industry.

Stakeholder Impact

• The transactions have no immediate impact on shareholders, employees, customers, suppliers, or creditors.
• The transfers are part of the CEO's personal financial planning and do not affect the company's operations.

Key Dates

Keywords

Amgen, Robert Bradway, stock transfer, grantor retained annuity trust, GRAT, irrevocable trust, SEC Form 4, insider trading, beneficial ownership